# A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

> **NCT06028230** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 70 (actual)

## Conditions studied

- Hidradenitis Suppurativa

## Interventions

- **DRUG:** SAR444656 (KT-474)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06028230
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-09-29
- **Primary completion:** 2025-10-09
- **Final completion:** 2025-11-12
- **Target enrollment:** 70 (ACTUAL)
- **Why stopped:** Sponsor decision. Not related to safety concern.
- **Last updated:** 2025-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06028230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06028230, "A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06028230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*